Ionis Pharmaceuticals (NASDAQ:IONS) Q3 results:
Revenues: $168M (+15.9%); Spinraza royalties: $82M (+17.1%).
Global Spinraza sales up 25% ytd to over $1.5B.
Net income: $26M (+620.0%); non-GAAP net income: $39M (+44.4%); EPS: $0.18 (+700.0%).
Initiate Phase 3 program for AKCEA-TTR-Lrx this quarter.
2019 guidance: Revenue: ~$1B from >$725M; net income: >$300M from net income positive.
Shares up 4% premarket on light volume.
Previously: Ionis Pharmaceuticals EPS beats by $0.60, beats on revenue (Nov. 6)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.